Observational Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Dec 7, 2020; 26(45): 7232-7241
Published online Dec 7, 2020. doi: 10.3748/wjg.v26.i45.7232
Figure 1
Figure 1 Plasma ADAMTS13:AC and VWF:Ag levels in patients with hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy treatment. A: ADAMTS13 activity (ADAMTS13:AC) levels were significantly higher in hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy treatment with stable disease (SD) + partial response (PR) than in those with progressive disease (PD) (P < 0.05); B: VWF antigen (VWF:Ag) levels were not different between patients with SD + PR and PD; C: VWF:Ag/ADAMTS13:AC ratio was significantly lower in patients with SD + PR than in those with PD (P < 0.05). SD: Stable disease; PR: Partial response; PD: Progressive disease; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: Ratio of VWF:Ag to ADAMTS13:AC.
Figure 2
Figure 2 Plasma vascular endothelial growth factor levels in patients with hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy treatment. A: Vascular endothelial growth factor (VEGF) levels were significantly lower in hepatocellular carcinoma patients with stable disease + partial response than in those with progressive disease (P < 0.05); B: Patients with high VEGF levels (> 100) had higher platelet levels than those with low VEGF levels (≤ 100) (P < 0.05); C: Patients with high Von Willebrand factor antigen (VWF:Ag)/ADAMTS13 activity (ADAMTS13:AC) ratio (> 2.7) had higher VEGF levels than those with low VWF:Ag/ADAMTS13:AC ratio (≤ 2.7). VEGF: Vascular endothelial growth factor; SD: Stable disease; PR: Partial response; PD: Progressive disease; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: Ratio of VWF:Ag to ADAMTS13:AC.

  • Citation: Takaya H, Namisaki T, Moriya K, Shimozato N, Kaji K, Ogawa H, Ishida K, Tsuji Y, Kaya D, Takagi H, Fujinaga Y, Nishimura N, Sawada Y, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. World J Gastroenterol 2020; 26(45): 7232-7241
  • URL: https://www.wjgnet.com/1007-9327/full/v26/i45/7232.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v26.i45.7232